what do glp 1 agonists do GLP-1 GLP-1 Agonists in Cardiovascular Diseases:

Evers said the Pharmacare program in the majority of provinces, including in Atlantic Canada, does not cover the cost of GLP-1 drugs for obesity because it has not yet been recognized as a chronic disease

J., Chen, N., Makhijani, P., Winer, S., Furman, D., & Winer, D

Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk was published in Nature Cardiovascular Research in April 2024

Collectively, numerous retrospective and large database studies have identified potential benefits of GLP-1RA in ocular disease, indicating a need for prospective trials to more definitively identify protective effects and integrate this medication class into the ophthalmology toolbox

In fact, a double-masked, placebo-controlled study found that Byetta (exenatide, AstraZeneca), a GLP-1 receptor agonist for diabetes, lowered intracranial pressure (ICP) by 5.7 cm H 2 O within 2.5 hours in women with active IIH ( P = .048), a benefit that was sustained across 12 weeks

Canada's Drug Agency has recommended that public plans cover Mounjaro with a discount of 25 to 49 per cent off list price at higher dosages [Source: theglobeandmail.com/business/economy/article-canada-drug-agency-mounjaro-recommendation-type-2-diabetes/]